A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and

Recruiting

99 years or below

All

Phase 3

1 Location

Brief description of study

The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding sub-score (RBS) greater than or equal to 1 or an absolute RBS less than or equal to 1 .

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ulcerative colitis
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 829889

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Brief description of study

Eligibility of study

Find a site

Interested in the study